Clinical trial NCT00027248: Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections
Official title: Phase III, Randomized, Open-Label Study to Assess the Safety and Efficacy of Topical Administration of MBI 226 1.0% Gel Versus Standard Medical Care in Patients Undergoing Non-Cuffed, Short-Term Arterial and/or Central Venous Catheterization
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Sepsis
Bacteremia
Fungemia
Keywords: central venous catheter
bloodstream infection
CVC
catheter colonization
local catheter site infection
Lead sponsor: BioWest Therapeutics Inc
Sponsor class: INDUSTRY
First posted: 2001-11-30
Enrollment: 1400
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Central venous catheters (CVCs) are used in patient care for such purposes as the administration of medication, fluids, blood products and for functions such as hemodialysis and plasmapheresis. However, the use of CVCs can cause complications such as life-threatening bloodstream infections (BSI).

BSIs are caused by organisms from the skin's surface tracking down the catheter's outer surface. The organisms grow on the catheter surface (catheter colonization) which is followed by seeding into the bloodstream. BSIs can be difficult to treat and the mortality rate is as high as 35% in Intensive Care patients with a catheter-related BSI. It is estimated that up to 70,000 patients in the US die each year from catheter-related BSI.

MBI 226 is a new drug that, when applied to the skin surrounding the catheter insertion site, may prevent organisms on the skin from migrating down the catheter and entering the bloodstream and therefore decrease the incidence of catheter-related BSI in patients with CVCs.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing non-cuffed arterial and/or central venous catheterization.
* Patients able to give signed informed consent.
* Concurrent antibiotic therapy is permitted.

Exclusion Criteria:

* Treatment with an experimental topical, antibacterial, or antifungal drug within the previous 30 days.
* Patients who are scheduled to receive catheters impregnated/bonded with an antimicrobial substance.
* Patients requiring arterial or central venous catheterization for less than 48 hours or longer than 28 days.
* Second or third degree burn patients.
* Patients with a suspected or known bloodstream infection or local catheter insertion site infection.
* Patients with a known allergy to adhesive tape or adhesive bandages.
* Patients with a medical condition that the Investigator believes may interfere with the safety of the patient or the intent or conduct of the study.
* Routine non-complicated post-operative CABG patients.
* The disinfection procedure for catheter insertion did not include povidone-iodine.

Primary outcomes:
measure: Reduction of catheter-related bloodstream infection
Secondary outcomes:
measure: Reduction of catheter colonization
measure: Reduction of local catheter site infection
Other outcomes:
Locations:
city: Lake Bluff
country: United States
facility: Omnicare Clinical Research Inc.
state: Illinois
Study officials:
affiliation: BioWest Therapeutics Inc
name: Jim Pankovich
role: STUDY_DIRECTOR
References: